These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24247054)

  • 1. Metabolic issues in psychotic disorders with the focus on first-episode patients: a review.
    Britvic D; Maric NP; Doknic M; Pekic S; Andric S; Jasovic-Gasic M; Popovic V
    Psychiatr Danub; 2013 Dec; 25(4):410-5. PubMed ID: 24247054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotics.
    Kozumplik O; Uzun S; Jakovljević M
    Psychiatr Danub; 2010 Mar; 22(1):69-74. PubMed ID: 20305594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome with the atypical antipsychotics.
    Pramyothin P; Khaodhiar L
    Curr Opin Endocrinol Diabetes Obes; 2010 Oct; 17(5):460-6. PubMed ID: 20717020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic complications of schizophrenia and antipsychotic medications--an updated review.
    Yogaratnam J; Biswas N; Vadivel R; Jacob R
    East Asian Arch Psychiatry; 2013 Mar; 23(1):21-8. PubMed ID: 23535629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abstinence, anticipation, reduction, and treatment (AART): a stepwise approach to the management of atypical antipsychotic side effects.
    Kennedy A; Tapp A; Kelly WS; Kilzieh N; Wood AE
    Essent Psychopharmacol; 2006; 7(1):1-14. PubMed ID: 16989288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic abnormalities in an early psychosis service: a retrospective, naturalistic cross-sectional study.
    Curtis J; Henry C; Watkins A; Newall H; Samaras K; Ward PB
    Early Interv Psychiatry; 2011 May; 5(2):108-14. PubMed ID: 21470374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Ellinger LK; Ipema HJ; Stachnik JM
    Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 'boon and bane' of antipsychotic-induced metabolic syndrome.
    Venkatasubramanian G
    Acta Psychiatr Scand; 2009 Dec; 120(6):500-1; author reply 501. PubMed ID: 19489746
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis.
    Thompson A; Hetrick SE; Alvarez-Jiménez M; Parker AG; Willet M; Hughes F; Gariup M; Gomez DL; McGorry PD
    Aust N Z J Psychiatry; 2011 Sep; 45(9):740-8. PubMed ID: 21827345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go?
    Eapen V; John G
    Australas Psychiatry; 2011 Jun; 19(3):232-5. PubMed ID: 21682621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic side effects of second generation antipsychotics in drug-naïve patients: a preliminary study].
    Diurni M; Baranzini F; Costantini C; Poloni N; Vender S; Callegari C
    Riv Psichiatr; 2009; 44(3):176-8. PubMed ID: 20066804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antipsychotic prescription assessment in general practice: metabolic effects].
    Gignoux-Froment F; de Montleau F; Saravane D; Verret C
    Encephale; 2012 Dec; 38(6):453-9. PubMed ID: 23200610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When essential medications provoke new health problems: the metabolic effects of second-generation antipsychotics.
    Stein K
    J Am Diet Assoc; 2010 Jul; 110(7):992-1001. PubMed ID: 20630154
    [No Abstract]   [Full Text] [Related]  

  • 20. Weight gain--as possible predictor of metabolic syndrome.
    Grahovac T; Ružić K; Dadić-Hero E; Sepić-Grahovac D; Sabljić V
    Psychiatr Danub; 2011 Mar; 23(1):105-7. PubMed ID: 21448110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.